Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Current Opinion in Pharmacology|July 5, 2011
Modeling complex neuropsychiatric disorders with human induced pluripotent stem cellsBrian T D Tobe, Evan Y Snyder, Jeffrey S NyeCurrent Biology : CB|July 19, 2002
Glycogen synthase kinase-3beta modulates notch signaling and stabilityDaniel R Foltz, Michelle C Santiago, Bridget E Berechid, et al.Experimental & Molecular Medicine|November 16, 2013
Implications and limitations of cellular reprogramming for psychiatric drug developmentBrian T D Tobe, Michael G Brandel, Jeffrey S Nye, et al.Pediatric Neurology|May 29, 2012
Adaptive behavior outcomes in infants treated with adjunctive topiramateSeth Ness, Mike J Todd, Steven Wang, et al.The Journal of Biological Chemistry|December 23, 2004
Intracellular retention of caveolin 1 in presenilin-deficient cellsDouglas R Wood, Jeffrey S Nye, Ned J C Lamb, et al.Headache|November 23, 2006
Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safetyPaul Winner, Astrid Gendolla, Catherine Stayer, et al.American Journal of Medical Genetics|February 22, 2002
Possible association of NTDs with a polyhistidine tract polymorphism in the ZIC2 geneLúcia Y Brown, Susan E Hodge, William G Johnson, et al.Journal of Clinical Pharmacology|April 16, 2005
Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjectsCaiping Yao, Arash Raoufinia, Michael Gold, et al.Neuropsychiatric Disease and Treatment|March 5, 2014
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's diseaseKlaus Hager, Alan S Baseman, Jeffrey S Nye, et al.Epilepsia|October 1, 2010
Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of ageIhab G Girgis, Partha Nandy, Jeffrey S Nye, et al.Pageof 3